1 boom reshapes Connecticut’s obesity
The rise of GLP-1 weight-loss medications like Ozempic and Wegovy is significantly impacting the bariatric surgery industry in Connecticut. While surgery volumes have declined, health systems are increasingly positioning these two approaches as complementary rather than mutually exclusive.
Why it matters
This shift represents a major transformation in the obesity-treatment market, forcing traditional medical providers to adapt their business models to accommodate pharmaceutical-led weight management.
🔒 GLP-1 boom reshapes Connecticut's obesity-treatment industry
The article reports on industry trends and business shifts without taking a stance on the efficacy or ethics of the treatments.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in